Journal
GENOMICS
Volume 102, Issue 4, Pages 243-249Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.ygeno.2013.06.007
Keywords
Multiple myeloma; Plasma cell leukemia; Cell cycle genes; Overall survival; Time-to-progression
Funding
- IGA of The Ministry of Health [NT11154, NT13190, NT12130]
- Ministry of Education, Youth and Sports [MSM0021622434]
- project (Ministry of Health, Czech Republic) for conceptual development of research organization (University Hospital Brno) [65269705]
- Czech Science Foundation [GAP304/10/1395]
Ask authors/readers for more resources
The objective of this study was to describe co-expression correlations of cell cycle regulatory genes in multiple myeloma (MM) and plasma cell leukemia (PCL). Our results highlight the presence of dynamic equilibrium between co-expression of activator and inhibitor gene sets. Moreover inhibitor set is more sensitive to the activator changes, not vice versa. We have shown that CDKN2A expression is associated with short-term survival in newly diagnosed MM patients (survival was 30.3 +/- 3.9 months for 'low' expressed and 7.5 +/- 5.6 months for 'high' expressed group, p < 0.0001). Moreover low-expression CDKN2A group showed time-to-progression benefit in newly diagnosed patients (remission was 20.8 +/- 3.6 months for 'low' and 8.4 +/- 2.7 months for 'high' expressed group, p < 0.0001) as well as in whole studied cohort of MM patients (remission was 20.8 +/- 2.8 months for 'low' and 9.8 +/- 1.1 months for 'high' expressed group, p < 0.0001). The overexpression of inhibitors can be explained as a compensatory reaction to growing oncogenic stress. (C) 2013 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available